AP128 Vaccine Shows Preliminary Safety in Stage IV CRC
Scott Kopetz, MD, PhD, FACP, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.
Scott Kopetz, MD, PhD, FACP, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.
The AP128 vaccine was well-tolerated as a monotherapy and in combination with the anti-PD-1 agent, ezabenlimab in patients with stage IV colorectal cancer treated in the KISIMA-01 clinical trial. Preliminary data also suggest this therapy may induce immune-mediated responses seen in the peripheral circulation and increased infiltration of TILs into liver metastases, explains Kopetz.
The KISIMA-01 study is ongoing and investigating the efficacy of the agent alone and in combination with ezabenlimab.
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
